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Abstract
Background: Epilepsy is the most common brain disease in dogs. Recently, diets have been reported to have a
positive impact on seizure activity and behaviour in various species including dogs with idiopathic epilepsy (IE).
Historically, classic high fat ketogenic diets (KD) and medium chain triglycerides (MCT) KD have been successfully
used to manage drug-resistant epilepsy. Similarly, an MCT enriched diet has been shown to improve seizure control
and behavioural comorbidities in some dogs with IE. However, it is unknown whether an MCT dietary supplement
(DS) may provide similar positive effects.
Methods: A 6-month prospective, randomised, double-blinded, placebo-controlled, crossover, multicentre
dietary trial is designed comparing a 9% metabolic energy based calculated medium-chain triglyceride (MCT)
oil supplement to a conventional ‘control’ DS. Only dogs which will have an International Veterinary Epilepsy
Task Force Tier II level like diagnosis of IE which satisfied the following inclusion criteria are included: age
between 6 months and ≤ 12 years; weighing between 4 and ≤ 65 kg; unremarkable interictal neurological
examinations; no clinically significant findings on routine laboratory diagnostics; unremarkable brain MRI scan;
have had at least 3 seizures in the previous 3 months prior to enrolment; treated with at least one ASD and
being classified as resistant. All dogs are fed initially for 90 ± 2 days with either the control oil or the MCT oil
alongside their normal diet, followed by 97 ± 2 days with the other supplement including a 7-day washout
period. Overall, the aim is to recruit thirty-six patients at five different centres and to investigate the effect of
MCTs as DS on seizure activity, tolerability, behavioural comorbidities and quality of life (QoL).
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Discussion: Dietary interventions are rarely studied in a standardised form in veterinary medicine. The
background diet, the cohort of animals and ASD received is standardised in this prospective diet trial to
ensure representative data about the potential effect of MCT DS. If the study data confirms former findings,
this would provide further evidence for the efficacy of MCTs as a management option for canine epilepsy.
This publication should offer a repository of trial conditions and variable description with forecasted statistical
analysis.
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Background
Epilepsy, defined by the disposition to having seizures, is
the most common chronic neurological disease in humans
and dogs [1, 2]. Within the UK alone, epidemiological
studies have revealed that an estimated 0.6% of dogs are
affected by idiopathic epilepsy (IE) [3]. Epilepsy is a major
risk to health and welfare in dogs. This neurological dis-
order has been associated with physical, cognitive and
neurobehavioural comorbidities and increased risk of pre-
mature death [4].
Currently, pharmacotherapy with seizure suppressing
drugs (“anti-epileptic drugs ”or “anti-seizure drugs” (ASD))
represents the most important form of treatment in veter-
inary medicine. Epileptic patients are usually treated on a
chronic, often life-long basis [4]. However, permanent ASD
administration is characterised by determining the fine bal-
ance between benefits and disadvantages of ASDs. The
seizure-suppressing effects of ASDs might be outweighed
by unfavourable side effects including polyphagia, polydip-
sia, polyuria, restlessness, lethargy or ataxia [5]. Owners of
dogs with IE are often worried about the level of sedation
and ataxia induced by ASDs, their dog’s seizure frequency,
and polypharmacy affecting their own and their pets’ qual-
ity of life (QoL) [6].
Furthermore, despite well-established ASD therapies,
over two thirds of dogs with epilepsy continue to experi-
ence seizures in the long-term and fail to achieve total epi-
lepsy control [7–9]. Up to 30% of these dogs treated with
two or more ASDs continue to experience seizures with a
less than 50% reduction in seizure frequency [8, 10–12].
This emphasises the need for new therapeutic interven-
tions to improve the QoL of dogs with IE [7, 13–15].
Various diets, especially ketogenic diets (KD), have
been shown to reduce frequency and severity of seizures
in humans with epilepsy and in rodent models of epi-
lepsy [14, 16–21]. Lifestyle variables, such as the diet of
dogs with IE, have also been recognised both anecdotally
and in published literature as having an impact upon
seizure activity and behaviour [22–25]. For example, a
trial of eight dogs with epilepsy treated with an exclusion
diet was reported in 2004 with seven dogs achieving a
reduction in seizure frequency [26]. Unfortunately, the
exact mechanism leading to the anti-epileptic and/or
anti-seizure properties of KDs has not yet been fully elu-
cidated, highlighting the need for more research, espe-
cially in veterinary medicine, to confirm the effects of
diet in dogs with IE.
The ketogenic diet was first used in human epilepsy to
mimic the metabolic state of fasting, as fasting was shown
to have anti-seizure effects [27]. Under conditions of low
carbohydrate intake, such as fasting, the liver metabolises
triglycerides and releases fatty acids and subsequent ke-
tone bodies into blood circulation, a process known as ke-
tosis [28]. The ketone bodies replace glucose as the main
source of energy in the brain [29]. A rise in brain ketones
has been suggested to evoke anti-epileptic properties [30].
The ketone body Beta-hydroxybutric acid (BHB) has been
shown to reduce seizure-like neuronal activity and is
thought to be mediated via KATP channel activity and inhi-
biting GABAB signalling in a Drosophila in-vitro model
[31]. Similarly, intraperitoneal injection of BHB led to in-
creased BHB serum concentrations and prolonged onset
of seizures in a rat seizure model accompanied with neu-
roprotective effects observed in histopathology [32].
Other, newer in-vitro studies assumed BHB as having neu-
roprotective function by direct gene regulation and pro-
motion of brain-derived neurotrophic factor (BDNF)
expression [33]. Apart from BHB, other in-vitro and
in-vivo studies in rodent epilepsy models on other ketone
bodies, such as acetone or acetoacetate, also indicated
anticonvulsant action, ion channel interaction and poten-
tial synergistic role in ketogenic diets [34–38]. Many stud-
ies have reported the anti-seizure effects of different
ketogenic diets and as such a myriad of hypotheses have
been generated for the mechanisms of action [39–42].
Proposed mechanisms behind this dietary intervention in-
clude preventing neuronal hyperexcitability, direct inhib-
ition of ion channels, influencing mitochondrial functions
and altering amino acid metabolism to influence specific
inhibitory neurotransmitter production [43–45].
At present, it is unclear whether the original KD would
prove to be an effective anti-epileptic management option
in dogs. To improve palatability and ketonemia, a variant
of ‘classic‘KD was introduced in 1971 by Huttenlocher
Berk et al. BMC Veterinary Research          (2019) 15:181 Page 2 of 14
[46]. This subtype utilises medium chain triglycerides
(MCT) as fat resource found as being more ketogenic than
long chain triglycerides (LCT) [47]. Up to date, many re-
search groups found that MCT-KD had also good anti-
seizure properties [16, 41, 48]. As dogs have a higher cap-
acity for ketone body utilisation, it is hard to induce and/or
maintain clinically effective levels of ketosis and anticonvul-
sant efficacy in dogs comparable to human medicine [49].
In contrast, MCTs are considered also as being more keto-
genic in dogs due to subsequent transportation without
pancreatic response and primarily metabolization into ke-
tone bodies in the liver [39, 48–50]. MCT-KD came there-
from more into research focus as the ketogenic diet for
dogs [23, 24, 49, 51].
The main constituent of MCT-KD are normally octa-
noic (C8, caprylic) and decanoic (C10, capric) triglycer-
ides (TAGs) [52, 53]. A recent in-vitro study has
revealed decanoic acid acts as a non-competitive AMPA
receptor antagonist that results in direct inhibition of
excitatory neurotransmission, and thus exerts an anti-
convulsant effect [54]. In comparison, octanoic acid
alone revealed no anti-epileptic effects in in-vitro studies
[55], but enhanced anticonvulsive properties in mice,
when orally co- administered with C10 [56]. Ongoing re-
search focusing on in vitro and rodent models also
highlighted the importance of medium chain fatty acids
with specific branching as anticonvulsant [57, 58].
In dogs, consumption of an MCT-enriched diet (10%
of total formula calories with C8, C10, C12) leads to sig-
nificant elevation in BHB concentration and improved
seizure control [24, 45, 59–61]. MCT intake also appears
to be linked to a significant improvement in attention-
deficit hyperactivity disorder (ADHD) -related behaviour
and fear/anxiety in dogs with epilepsy [23] and to have
cognition-improving effects in aged dogs [61]. Recent re-
search confirmed the observed benefits from MCT
enriched kibble diet in aged dogs with cognitive dysfunc-
tion syndrome (CDS) in a prospective double blinded
placebo controlled study design [62].
In conclusion, albeit past research provides a solid
base, the exact metabolic mechanisms governing anti-
seizure effects from BHB and/or MCT remain elusive,
not only in humans, but especially in dogs. Whether
MCTs can be an effective anti-seizure agent and show
neuroprotective and anxiolytic effects in dogs with IE re-
quires further investigation.
We hypothesise MCTs administered as a daily supple-
ment will reduce seizure frequency and severity, reduce the
level of ASD side effects and positively influence behavioural
comorbidities of epilepsy in dogs. The primary aims of this
clinical study are to investigate the short- term influence of
MCTs given as a DS on seizure occurrence, disease progres-
sion, drug-response, behaviour and QoL of dogs with IE.
Twelve weeks of feeding is considered the minimal duration
to allow short-term evaluation of efficacy and safety for diets
[24, 59]. Using the same test system as in our former study
which for the first time demonstrated the efficacy of an
MCT- enriched kibble diet [24] will help us draw compari-
sons between studies and provide results in a reasonable
time frame.
The rationale of the current study is not only to
corroborate the former results [4, 63] using a supple-
ment rather than using a complete manufactured diet,
but also to investigate the broader effects of MCTs
on epilepsy and its comorbidities including their ef-
fects on cognition and behavioural comorbidities. This
study should provide further information about the
role of MCT ingestion and its importance in canine
epilepsy management [48, 49].
Methods and study design
Recruitment
Participants are informed about this trial through differ-
ent media in the UK, Germany, Austria, Switzerland and
Finland. For advertisement, individual flyers and web-
sites are made supporting the recruitment process. Epi-
lepsy phenotype is determined using previous medical
history and a standardised clinical history questionnaire
(Additional file 1). Throughout this study, all dogs are
recruited by a two-step screening system. Initially, all in-
terested owners are asked to complete an online
pre-study questionnaire capturing important data about
the signalment, history, clinical appearance, diagnostics
and treatment of their dog’s IE. All applications are indi-
vidually screened and selected in batches based on de-
fined criteria and details then send to each study site.
Study design
A 6-month randomised, double-blinded, prospective,
multicentre, dietary crossover trial is designed to com-
pare two oil-DSs (MCT oil, control oil (olive oil)) in
dogs with IE (Figs. 1 and 2). The experimental unit is
each individual dog. Law et al., 2015 demonstrated a sig-
nificant difference in 21 dogs completing the study, with
a drop-out rate of approximately 30%. In this study, we
aim to enrol a total of thirty-six (36) dogs between five
different study sites in three different countries in Eur-
ope (UK: Royal Veterinary College and, Pride Veterinary
Centre, Germany: Tierarztpraxis Strassenheim, Tierarzt-
praxis Bathen-Nöthen and, Tierärztliche Hochschule
Hanover, Finland: University Helsinki).
The monitoring site for this trial is the Clinical Investiga-
tion Centre (CIC) of the Royal Veterinary College (RVC),
which oversees the logistical progression of the study under
the supervision of the Study Monitor and leader. This study
is conducted in accordance with veterinary GCP guidelines
((i) International Cooperation on Harmonisation of Tech-
nical Requirements for Registration of Veterinary Products
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(VICH) GL9 Good Clinical Practices (July, 2001), (ii) The
European Agency for the Evaluation of Medicinal Prod-
ucts (EMEA) Guideline on statistical principles for veter-
inary clinical trials, EMEA/CVMP/816/00-FINAL (June 5,
2002)). The study is approved by the Clinical Research
Ethical Review Board (URN 2016 1558).
Each dog is randomly assigned using block randomisa-
tion to begin their first dietary period with either MCT or
the placebo DS. The owner and investigators will not be
informed of diet group assignment for each dog. All re-
cruited dogs will be fed initially for 90 ± 2 days with either
the control DS or the MCT DS alongside their normal
diet, followed by 97 ± 2 days with the other supplement
alongside their normal diet. The second feeding period in-
cludes the first week as a wash out period, which will not
be considered in the statistical analysis. Each dog is evalu-
ated on-site at the enrolment visit (−V1), and at the end of
each 90 ± 2-day or 2nd 97 ± 2 dietary period (V2 = 90 ± 2
days, V3 = 187 ± 2 days). Between on-site visits, owners
will be contacted by phone to check for any difficulties
arisen during the study period and to ensure compliance
(TC1 = 45 ± 2, TC2 = 142 ± 2 days).
For all trial participants, the dog should be fed twice
daily with their regular diet, with the half amount of the
total daily oil requirement. A total of 9% of the daily
metabolic energy per day is from the oil. ASD treatment
will not be withheld at any point nor changed in this
study, however, owners will be allowed to stop their par-
ticipation in the trial at any time point, as requested by
the Clinical Research Ethical Review Board. Dogs that
have been receiving other oils or oil type DS previously
can take part in this study when there has been a
pre-wash out period of at least 14 days before visit 1. All
owners are asked to keep the diet and drug treatment
constant throughout the study period and to document
any adverse events.
STUDY PERIOD
Pre-
Enrolment
Enrol-
ment
Allocation Post-allocation Close-out
TIMEPOINT -V1 -V1 V1 TC1 V2 TC2 V3 V3
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation: Block 
randomization X X
INTERVENTIONS:
[Intervention: AB, 
MCT-DS = 1st]
[Intervention BA, 
MCT-DS = 2nd]
ASSESSMENTS:
[Baseline: Body 
weight, age, body 
temperature 
examination, drug 
serum concentration]
X (X) X (X) X X
[Outcome: 
Examination, Seizure 
data, beta-
hydroxybutyrate, bile 
acids stimulation test, 
VAS scoring 
metabolome, 
microbiome]
X X X X
[List other data 
variables: hematology, 
biochemistry, VAS, 
behavior testing, 
questionnaire data, gait 
analysis]
X X X X
Fig. 1 SPIRIT aligned schedule of enrolment, interventions, and assessments
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The ‘Animal Research: Reporting in-Vivo Experi-
ments’ (ARRIVE) [64] and the Schedule Of Enrolment,
Interventions, And Assessments (SPIRIT) reporting
guidelines [65] have been considered and integrated
into this study protocol were applicable (see also Add-
itional file 2) .
Fig. 2 Study Design A 6-month randomised, double-blinded, prospective, multicentre, dietary crossover trial is designed to compare two oil
dietary supplements (MCT oil, Control oil (=olive oil)). Both oils are given as 9% of their daily metabolic energy requirements. All dogs are aimed
to be fed initially for 90+/− 2 days with either the control dietary supplement or the MCT dietary supplement alongside their normal diet
followed by 97+/− 2 days (including initial one-week wash-out period, 7 days) with the other supplement alongside their normal diet. Another
follow-up study about the long-term effects of MCT oil as an open-label use is subsequently planned after the individual patient has completed
the main clinical trial
Berk et al. BMC Veterinary Research          (2019) 15:181 Page 5 of 14
Investigational animals – study phenotype
Only dogs that satisfy all of the inclusion criteria and to
whom none of the exclusion criteria apply will be en-
rolled and receive at enrolment a unique study number
for identification purposes. All owners must give written
informed consent to participate in the study and agree
to fulfil all requirements of the study. All mixed or
pure-breed dogs participating in this study are privately
owned. The pet dogs should be at least 6 months of age
on Day 0 and weigh at least 4 kg. To be recruited, dogs
must be in general good health and have an unremark-
able interictal neurological examination for a dog on
ASD treatment. Additionally, each dog must have met in
general the International Veterinary Epilepsy Task Force
(IVETF) tier II confidence level diagnosis of IE [4]. The
current IVETF statement is, however, not yet clear about
the importance of age in Tier II or above. In this study,
dogs older than 6 years will be included as long they
meet all the other inclusion criteria. Each dog will need
to be treated with and resistant to least one ASD to be
recruited. Drug-resistant patients are defined in line with
the IVETF’s definition of therapeutic success Category 3
[63]. In addition, each patient must have a required seiz-
ure frequency of at least three or more seizures in the
last 3 months despite properly monitored pharmacother-
apy prior to enrolment. Any dog with a known cause of
epilepsy (structural epilepsy) e.g. brain neoplasm, brain
trauma, encephalitis and meningitis are excluded. Any
acute medical or surgical condition, pregnancy, lactation,
history of pancreatitis or history of chronic or acute
renal, hepatic or cardiac failure would lead to the pa-
tient’s exclusion. Furthermore, dogs on drugs, diets or
DS which could influence the metabolism of phenobar-
bitone, imepitoin or other ASD given during the trial are
not included.
Palatability
Altering the diet characteristics with oil supplementation
can be at the expense of palatability and influence a dog’s
eating behaviour. The mean food intake, as a percentage,
can be calculated for each period and used to assess the
dogs eating preference. An intake ratio (IR) can represent
consumption rates. In this clinical trial successful food in-
take is essential. A small pilot study will be conducted in
advance to ensure palatability and comparability of oils
used to guarantee overall diet acceptance.
Baseline diet
The baseline diet will be nutritionally assessed for each pa-
tient, as its composition might amplify or influence the
anti-seizure properties of MCTs. This includes the individ-
ual feeding type (commercial vs. home-made; subtypes)
and utilised feed components (brand, formulation and
type). This information is then used to create an average
main nutrient profile on a dry matter basis (MNP: crude
protein, crude fat, crude ash, crude fibres, nitrogen free
extracts (Nfe), moisture). For this purpose, analytical data
will be requested from each company. If available, the in-
clusion of additional data from other relevant nutrients,
such as minerals, vitamins or fatty acids, will be consid-
ered. The hypothesised anti-seizure effects from MCT oil
supplementation should be then critically discussed in the
light of the patients’ whole diet.
Investigational veterinary dietary supplement
The details of the ingredients and the maintenance of
each oil are stored in the Dispenser File at the monitor-
ing site. The MCT DS used will only contain C8 and
C10 in a certain ratio and therefrom allow the investiga-
tors to extend the knowledge about the role of the single
medium-chain fatty acids (MCFAs) in the former publi-
cations used for cognition-enhancement in aged dogs
[61] and in dogs with IE [24, 59]. Both oil DS will be
commercially available. The DS will be then supplied by
the Study Monitor to the Investigator and will be stored
at room temperature in a locked room at each test site.
The dispenser educates the owner to keep the oil admin-
istration consistent throughout the study period. From
enrolment onwards, the owner is not allowed to change
or give any additional foods apart from the usual diet, or
other food supplementations during the study period.
Study procedures
As aforementioned, the owner is in contact with the in-
vestigator on the following occasions with a tolerance of
±2 days: enrolment visit (−V1) before the start of the
first dietary intervention period 1 (V1)); Day 45 (tele-
phone call 1 (TC1)); Day 90 (visit 2 (V2), before the
crossover and start of the second dietary intervention
period II); Day 142 (telephone call 2 ((TC2)), Day 187
for study completion (visit 3 (V3)).
For each on-site study visit, the investigator completes
the following tasks (a-e) to collect relevant data and
monitor the clinical progress of each patient, while other
parameter will only be collected depending on local con-
ditions (f-i):
(a) Body weight and temperature is recorded;
(b) Clinical and neurological examination is performed;
(c) Checks the owners’ documentation of seizure
occurrences by frequency, severity and subtypes
using a standardised logbook.
(d) Visual analogue score to measure level of sedation,
ataxia and quality of life;
(e) Blood samples for routine haematology, serum
biochemistry, thyroid profile, canine pancreatic
lipase (CPLI), beta-hydroxybutyrate (BHB), serum
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concentration of phenobarbitone and/or potassium
bromide and dynamic bile acid test are taken;
(f ) Saliva is collected in the morning of each study
visit;
(g) Fresh urine and faeces are collected;
(h) Behavioural tests on anxiety and cognition are
conducted;
(i) Gait measurements are conducted.
In order to assess the dog’s behaviour and QoL be-
tween the visits, a questionnaire is completed by the
owners, at the earliest 24 h in advance of the scheduled
study appointment (Additional file 3). The questionnaire
consists of five existing questionnaires covering multiple
aspects of behaviour, cognition, ADHD-related behav-
iour, appetite and QoL:
(1) Canine Behavioral Assessment & Research
Questionnaire (C-BARQ) [66]
(2) Attention deficit hyperactivity disorder rating scale
(ADHD-RS) [67]
(3) Canine cognitive dysfunction rating scale (CCDR)
[68]
(4) Dog Obesity Risk and Appetite Questionnaire
(DORA) [69]
(5) Evaluation of Quality of Life in Dogs with IE
(EpiQoL) [70].
All concomitant treatments and medications including
vaccines, anthelmintics and drugs for parasite prophy-
laxis for the patient are recorded by the Investigator on
each contact with the owner and is to be included in
parameter analysis. Any abnormal health observation
that is unfavourable and unintended and occurs after an
animal has been enrolled and fed with the dietary sup-
plement, regardless of whether it is considered to be
product-related, is an adverse event. The documentation
of adverse events includes the following details: a de-
scription of the adverse event; length of the adverse
event recorded in days; severity of the adverse event re-
corded using 1 =mild, 2 = moderate, 3 = severe and 4 =
serious; frequency of the adverse event measured using
1 = once, 2 = occasionally, 3 = regularly and 4 = ongoing;
concomitant treatment noted as 1 = none and 2 = yes;
and final outcomes consisted of 1 = resolved without fur-
ther effects, 2 = resolved with further effects, 3 = un-
changed, 4 = euthanasia and 5 = death. In reference to
the study objectives, seizure occurrences during the
study participation is not defined as an adverse event.
Any concomitant treatments during the study period is
recorded with details on indication, used products, given
strength, doses and length of treatments. Concomitant
changes of ASD medication or dosages throughout the
study lead to study exclusion.
Specification of the Study Variables (Additional file 4:
Table S1)
General physical and neurological examination and
laboratory diagnostics
A routine inter-ictal clinical and neurological examination
is performed at each study visit. All above mentioned
blood samples are analysed and added to the patients file.
Comparison of all blood parameters between the dietary
intervention periods is planned.
Seizure frequency, seizure days per months, inter-seizure
interval
The seizure frequency is recorded by the owners in the
‘Seizure Diary’ per dietary intervention period. Short-term
efficacy will be assessed over a 3-month period. Only gen-
eralised seizures will be counted toward the efficacy meas-
urement. The primary outcome parameter for seizure
frequency is ‘treatment success’: Treatment success is de-
fined as seizure freedom for a time-span exceeding three
times the longest inter-seizure interval (days) for an indi-
vidual dog considering the year preceding the study and
for a minimum of 3 months (time to 1st seizure) based on
owners’ documentations. [63]. Consequently, patients with
complete freedom of seizures or significant extension of
the inter-seizure interval will be considered treatment suc-
cess and treatment should thereafter be continued as
open-label to assess the seizure free rate e.g. the percent-
age of patients with short-term or long-term freedom of
seizures. Partial treatment success will only be assessed in
this study for dogs, which will remain in the study for at
least 3 months and have no change in treatment during
this period. Partial therapeutic success is defined as a sig-
nificant difference (reduction) in either: seizure frequency
(seizures/month), seizure days frequency per months, seiz-
ure cluster days frequency per months, seizure severity
measured by number of episodes of cluster seizures or sta-
tus epilepticus during a 3-month period between the
MCT and control periods. Finally, each dog will be classi-
fied as ‘seizure free’, if it experiences a 100% reduction in
seizure frequency, and as a ‘MCT responder’ if it experi-
ences at least 50% reduction in seizure frequency between
both dietary periods.
Seizure types
Information from the standardized Seizure Diary will be
used to define the type of seizures. Seizures will be clas-
sified according to the guidelines of IVETF [63]. In this
study, generalised seizures are the main focus of interest,
as they are better recognised by the owner and reported
to their vet [71]. A generalised epileptic seizure is an epi-
leptic seizure, which initial semiology indicates, or is
consistent with, more than minimal involvement of both
cerebral hemispheres. Generalised epileptic seizures are
conceptualised as originating at some point within, and
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rapidly engaging, bilaterally distributed networks, vegeta-
tive symptoms and loss of consciousness. Focal epileptic
seizures are conceptualised as originating within net-
works limited to one hemisphere. Cluster seizures are
defined as an episode where more than one seizure oc-
curs within a 24-h period [63]. Status epilepticus will be
defined as (a) continuous seizure activity for more than
5min or (b) two or more discrete epileptic seizures be-
tween which there is incomplete recovery of conscious-
ness (for generalized convulsive seizures) [63].
Behavioural comorbidities and cognition
The conducted five questionnaires, the VAS scoring and
the behavioural tests are used to evaluate the patients on
neurological and behavioural changes in terms of appetite,
cognition, trainability, anxiety, activity and ataxia at each
visit of this trial. The questionnaires and behavioural tests
will be completed during each of the three trial visits.
(a) Non-invasive behavioural tests:
 Anxiety testing [13, 72, 73]: Each dog will
undergo two non-invasive tests to assess anxiety
behaviour: (i) open field test (OFT); (ii) separ-
ation test (ST). The room setting including cam-
eras will be standardised to ensure consistency
between measurements. The recorded video clips
will be retrospectively evaluated. Known anxiety-
associated behaviours will be assessed in terms of
frequency, intensity (likert-scale grading 1–10)
and occurrence in percentage of overall time of
experiment [72, 74].
 Cognition testing: Each dog will undergo two
validated, non-invasive tests to measure different
aspect of cognition (task 1: food searching, task
2: problem solving) as formerly described in dogs
with and without epilepsy using the same scoring
system [75, 76]. The testing environment will be
prepared for both tasks in a standardised empty
room with no noise, smell or light distraction.
 Gait recording: At each visit the gait will be
video recorded and analysed retrospectively. Fifty
strides from a walking dog will be assessed and
then used to quantify the level of ataxia as
formerly described in detail [77, 78].
(b) Questionnaires: An alteration in individual
calculated scores for the questionnaires between the
visits indicates improvement or deterioration of
variables measured. Calculated scores are compared
between dietary periods, but also grouped by MCT
responder rate and seizure control in order to
elucidate associations and relationships.
i. Canine Behavioral Assessment & Research
Questionnaire (C-BARQ) [66]: The cBARQ
contains the following subscales used for future
comparison between both dietary periods:
trainability, stranger-directed fear, fear, owner-
directed fear, non-social fear, separation related
fear, attachment and attention seeking, chasing,
excitability and touch sensitivity. Findings will
be also compared to other more-targeted ques-
tionnaires, as subsequently listed.
ii. Attention deficit hyperactivity disorder rating scale
(ADHD-RS) [67]: ADHD-RS is a valid method to
assess attention and activity skills in dogs. Prede-
termined from the 13 items, two subscales (in-
attention (6 items, [0–3]) and activity–impulsivity
(7 items [0–3]) of the questionnaire are calculated
and will be compared between both dietary pe-
riods. Multivariate analysis will also include age-,
gender- and training-skills.
iii. Canine cognitive dysfunction rating scale
(CCDR) [68]: Cognitive abilities will be rated on
an owner-based report using the CCDR scoring
system with 13 behavioural items. The score
can help identify dogs which have clinical signs
seen with canine cognitive dysfunction (CCD).
A score of 0–39 is classified as normal, 40–49 at
risk and > 50 as CCD. Individual scores will be
compared between study periods.
iv. Dog Obesity Risk and Appetite Questionnaire
(DORA) [69]: A questionnaire of 34 items
grouped into three dog and four owner factors
is applied at each study visit to get reliable,
owner reported measure of the dogs eating
behaviour linked to each DS. Each subfactor is
rated by option scaled questions and in
numerical analysis transformed as a percentage
of the maximum between 0 and 100.
v. Evaluation of Quality of Life in Dogs with IE
(EpiQoL) [70]: A questionnaire of 7 themes with
36 questions compromising subunits (“Seizure
severity and frequency”, “Adverse effects of anti-
epileptic drug (AED)”, “Restrictions on the
carer’s life”, “Frustrations over caring for a dog
with IE”, “Carer distaste of AED adverse effects”,
“Carer anxiety around the seizure event”, “Per-
ceptions on rectal diazepam use”) are option
scaled rated by the owner and compared in
frequency.
(c) VAS: At each study visit the owner is asked to
complete a VAS for ataxia, sedation and overall
QoL using a line from 0 to 100 mm (0–100%). A
secondary intersecting line that presented best the
subjective severity should be set by the owner
perpendicularly on a provided measurement line. A
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perpendicular line at 0 mm represents
‘asymptomatic/normal’, while at 100 mm either the
dog shows ‘ataxia so severe that it is unable to walk’
or ‘sedation to the extent that it only sleeps’ or
‘QoL is so poor euthanasia is requested’. On
analysis, the length from 0 to the perpendicular line
will be normalised to baseline for statistical
comparison into a percentage value (0–100%,
negative = improvement, positive = deterioration).
Monitoring metabolic responses
At each study visit, blood is collected by venepuncture
using standardised operation procedures for haematol-
ogy, serum biochemistry, ASD serum concentrations
(phenobarbital, potassium bromide), cPLI, BHB and dy-
namic bile acid testing. The BHB and postprandial bile
acid sample is taken as one sample 2 h after feeding with
oil supplement. The cortisol level in saliva will be
assessed between study visits [79]. The samples will be
collected at the same time in the morning of each study
visit. Furthermore, serum, urine and faecal samples are
collected. These samples are used to investigate the me-
tabolome and microbiome, respectively [80].
Data analysis
After study completion, the data will be collated, and stat-
istical analysis will be performed using SPPS V24 (IBM
Deutschland GmbH, Ehningen, Germany) and Prism®
(GraphPad Software, San Diego, USA). Results will be
considered significant if after correction for multiple test-
ing the p value < 0.05.
For all baseline, efficacy and safety parameters, the fol-
lowing analysis will be performed (Additional file 4:
Table S1):
– Individual values will be listed and if appropriate
graphically presented per time point for each group.
– For the continuous parameters, descriptive statistics
will be calculated and tabulated per time point for
each group. If data are normally distributed (as
ascertained via plotting histograms of relevant
variables and using Kolmogorov-Smirnov test), the
mean and standard error will be plotted over time
for each group.
– For the categorical or discrete parameters, a
frequency table will be calculated and tabulated per
time point of each group. A graphical presentation
over time for each group will be made by means of a
bar or pie chart.
Comparisons between the DS groups are made using
match-paired Student’s t-tests for parametric data and Wil-
coxon matched-pairs signed rank test for non-parametric
data. The relationships between two variables are analysed
using Pearson’s correlation coefficient for parametric and
Spearman test for non-parametric data. Optionally, further
multiple comparison correction based will be applied on in-
dividual data sets. The presence of cluster seizures is com-
pared between DS periods using the McNemar test.
Statistical analysis is planned to be a combination of
univariate (UVA) and multivariate data analyses (MVA).
A mixed effect model might be considered. Statistical
testing will be adapted were appropriate (Additional file
4: Table S1).
Power calculation
Our previous study did indicate that the effect of MCTs
on seizure frequency can be detected with n = 21 dogs
[24]. Similarly, another study suggested twenty-two dogs
in each group being sufficient for showing significant
differences between two diet groups for seizure fre-
quency [51]. In conclusion, we aimed to recruit at least
36 dogs to reach a minimum of 22 dogs to anticipate a
usual patient dropout-rate of 30%.
Discussion
Using a crossover dietary trial approach, we will generate
data to investigate the value of MCT oil supplementa-
tion as a management tool for dogs diagnosed with IE
not responding to standard ASD(s). If clinically and sta-
tistically significant effects are observed between the
dietary periods, MCT oil has the potential to become an
easily adjustable add-on therapy for dogs with epilepsy.
This study will utilise a prospective, double-blinded
randomised placebo-controlled trial with a crossover de-
sign. Considering these specific study features in the de-
sign, we do not only follow international high quality
standards for clinical research, but also address potential
biasing effects in clinical veterinary trials [81, 82]. The
integration of a dietary crossover with placebo/control
period, double-blinding and block randomisation should
minimise the regression-to-the-mean, the placebo and
observer effects seen in other canine epilepsy trial in vet-
erinary medicine [83]. We are confident that this design
significantly increases the accuracy and representative
nature of our expected findings on the use of MCT oil
as nutritional add-on management in dogs with IE.
Regression-to-the mean arises often in clinical trials
when a variable is extreme on its first, but closer to the
mean on its second measurement or vice versa [84–87].
In canine epilepsy trials, usually an extreme (hardest-to--
treat) group is selected from an epileptic dog population
based on the measurement of a particular variable. In this
study, only dogs with idiopathic epilepsy TIER 2 level,
classified as ‘drug-resistant’ with a poor seizure control
are recruited, so that this phenomenon must be addressed
in the study design. If this effect is not considered, the
clinical trial or the interpretation of our obtained data can
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lead to incorrect conclusions, so must be then expected to
be inaccurate or incorrect [88] .
The placebo effect is a well-known phenomenon in hu-
man medicine [89], however, limited information about
the placebo effect exists in veterinary medicine to date
[90]. Reports so far described caregiver placebo effect es-
pecially in association to chronic anti-inflammatory or an-
algesic treatment in small animals [91–93]. A decrease in
seizure frequency of around 30% compared to baseline
has been noted in different trials in canine epilepsy as po-
tential placebo effects [83]. The occurrence of placebo ef-
fects are significantly associated with response expectancy
[89]. In canine epilepsy trials, the expectation from owners
is usually higher due to physiological stress, often poor
seizure control and the continuous negative impact on
their own QoL [70, 79, 94, 95] so that a notably subjective
influence on the dog can be more likely. A general run-in
period given by the recruitment process, where owners
are first enrolled on a waiting list and their dog are
checked on study criteria before giving the first treatment,
will also support to mitigate the response expectancy.
Another impact can derive from the Hawthorne effect
or also known as the observer effect. When study indi-
viduals are aware of being observed within a clinically
trial, their response to the trial situation can not only
modify, often falsify study variables. The Hawthorne ef-
fect can therefore also be seen as an pre-placebo expect-
ation [96]. Alike in epilepsy research in human medicine
[97], such type of reactivity should be considered as in-
fluencing factors from owners and their dogs in the de-
sign of canine epilepsy trials.
The integration of a dietary crossover in the mid of ob-
servation time, allows each participant to receive both
dietary interventions. Each study object will therefore
serve as its own control and reduce significant biasing ef-
fects [98]. Even though the retrospective baseline is docu-
mented, the data will be completely disregarded in most
of the analysis and only applied were appropriate. This ex-
clusion is to minimise the regression-to-the-mean and ob-
served placebo effect in other canine epilepsy trial in
veterinary medicine [83].
Keeping all involved individuals (tester, subject,
owners) blind from the used dietary supplement is an-
other attempt to eliminate bias and the expectancy from
owners seeing responses in their dog’s seizure control
after giving the specific DS. Not only observer, but also
investigator bias might otherwise provoke incorrect ob-
servations, so that using a double-blinded design is most
appropriate here. Describing the blinding methodology
is important to give veterinarians the ability to assess the
validity of the test results and apply in clinical environ-
ment [99] .
A core principal for clinical trials in human and veterin-
ary medicine is the randomisation [100, 101]. The process
of randomised allocation of each dog on its day of enrol-
ment is considered in this study as being essential. The
random assignment of each study subject to a predefined
block (1st DS (AB), 2nd DS (BA)) reduces the impact of
selection bias and increases the validity of the expected
study results. Furthermore, the detailed reports about the
allocation process makes it possible for practitioners to
critically review the impact of bias on study results and
make informed decisions regarding the treatment of their
own epileptic patients [102].
Overall, using not only a crossover design with a pla-
cebo/ control period, but also a block randomisation
protocol and blinding should limit all above mentioned
biasing effects to a possible maximum. Acting against
hypothetical, multi-sided bias by implementing described
trial features, should enable us to collect and assume not
only controlled, but also representative data about MCT
consumption in dogs diagnosed with IE.
Dropout is often used as an outcome measure in clinical
trials. But, in randomised clinical trial with epileptic pa-
tients, it appears to be higher than other clinical studies
and partly explained by trial design features thus providing
direction for future trial designs [103]. As a preventive
measure, the total amount of patients recruited will be
aimed to be increased by > 30% to ensure a sufficient
number of patients that will finish the trial. Law et al.
(2015) have shown an effect with 21 dogs finishing the
trial. Furthermore, in another study on ketogenic diet,
twenty-two dogs in each group were suggested to be suffi-
cient for showing significant differences between two diet
groups for seizure frequency [51]. Accordingly, we aimed
to recruit at least 36 dogs to reach a minimum of 22 dogs
factoring a usual dropout-rate of 30%.
Although study features will be implemented to pre-
vent massive biasing effects, limitations are in any clin-
ical trial and must be reflected critically on data analysis.
One limitation of this study design is that an intention
to treat analysis (ITTA) can be challenging or impossible
to perform. ITTA is an approach to the analysis in which
our recruited patients are evaluated as block rando-
mised, regardless of the dietary intervention they actu-
ally received [104]. This is especially hard to realise
when most or all dogs that dropout are within the first
study period, as was the case in our former MCT study
[24]. There is a chance that if randomisation is not carried
out carefully, that results could be skewed as study drop-
outs will not be included in the paired statistical analysis.
It is therefore of pivotal importance to document in detail
(and if possible, compare statistically) the reasons why
owners withdraw their dog from the study and during
which study period. As aforementioned in the last study
[24], the majority of the dropout dogs (7 out of 10) did
not complete the first respective randomised allocated
diet, hence there was no outcome measure at all for the
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remaining respective diet group. Using the last observa-
tion carried forward is not possible as there was no obser-
vation for the second diet.
Furthermore, utilising a statistical imputation method of
the outcome measure would require profound assump-
tions to be made on the missing outcome. Statistical im-
putation of outcome assuming the MCT and placebo diet
would be the same introduces bias towards the null. On
the other hand, imputation assuming a difference on the
probability of the outcome introduces bias towards the
treatment effect. Considering that the primary aim of the
study was to determine the anti-seizure efficacy of the ke-
togenic MCT diet, the utilising of a per protocol analysis
method is more suitable and logical [82].
Oil supplementation for dog owners as additional
treatment for general health or targeted to epilepsy man-
agement is a common practice [105]. As the clinical trial
aims to prove ketogenic MCT oil supplementation as
nutritional management for epileptic dogs, dietary char-
acteristics and acceptance must be considered. As a vari-
able, palatability is the measure of intake of a food that
indicates acceptance, or the measure of preference of
one food over another [55]. Food with different charac-
teristics can alter voluntary food intake by affecting pal-
atability, taste or flavour [56]. Excluding bias linked to
palatability in the main clinical trial, the food intake ratio
should be similar. The mean food intake, as a percent-
age, can be calculated for each period and was used to
assess the dogs eating preference. An intake ratio (IR) of
over 0.50 would represent equivalent consumption. If in-
take ratio (IR) for a feeding period was greater than 0.50
at 0.55, this would lead one to conclude that it was con-
sumed at a greater quantity [61]. Both oils will be proven
in advance in a small palatability study to be well toler-
ated, similar consumed and no food preference was ob-
served. Eating time might be increased when the oil DS
is given, and this may be due to ‘neophobia’ [57] - and
this may take time for the dogs to habituate to the pres-
ence of a new flavour/texture in their diet [58]. In sum-
mary, a good and similar palatability without any acute
gastrointestinal side effects should be concluded and
monitored in the prospective dietary trial.
Canine nutrition needs to be considered for epilepsy
management [60, 107–110]. Diet composition, content
and some of the DSs mentioned could influence phar-
macokinetic properties of ASDs and potentially modu-
late their efficacy [39, 61]. Owners of dogs with more
severe epilepsy phenotypes, as recruited for this study,
are likely to change unconsciously dietary regimes or DS
due to higher levels of psychological stress [70, 79, 106],
therefore owners were asked to keep diets and DS con-
stant throughout the trial. In addition, owners were
asked to daily monitor any changes in seizures, drugs
used, and potential adverse events seen. Nevertheless, a
balanced supply of all nutrients is routinely not checked
in first opinion practice and might play a role for the in-
terpretation of dietary effects occurring from MCT oil
supplementation. We will take great care of assessing
the baseline diet as aforementioned. However, each dog
will have a different baseline diet, which might influence
the results and could be seen as another limitation of
the study.
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